Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. OncologyPRO
  2. Meeting resources
  3. ESMO 2016

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Date

10 Oct 2016

Session

Sarcoma

Presenters

Nienke Lankheet

Citation

Annals of Oncology (2016) 27 (6): 483-492. 10.1093/annonc/mdw388

Authors

N. Lankheet1, I.M. Desar2, S.F. Mulder2, D.M. Burger3, C.M.L. van Herpen2, W.T.A. van der Graaf4, N.P. van Erp3

Author affiliations

  • 1 Pharmacy, Radboud University Medical Centre Nijmegen, 6525 GA - Nijmegen/NL
  • 2 Medical Oncology, Radboud University Medical Centre Nijmegen, Nijmegen/NL
  • 3 Pharmacy, Radboud University Medical Centre Nijmegen, Nijmegen/NL
  • 4 Medical Oncology, Royal Marsden NHS Foundation Trust, London/GB
More

Resources

Login

Abstract 2132

Background

Oral oncolytics imatinib (IMN), sunitinib (SNN) and pazopanib (PZN) show a high interpatient variability in pharmacokinetics. For IMN, SNN and PZN a relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of this study was to monitor how many patients reached adequate trough levels (Cmin) after dose optimization in daily practice.

Methods

An observational study was performed in a cohort of patients treated with IMN, SNN or PZN of whom multiple drug levels were measured between August 2012 and April 2016. Patients' characteristics were collected by reviewing medical records. Drug levels were measured using LC-MS/MS and Cmin were estimated using the algorithm of Wang et al.

Results

396 trough levels were determined in 109 patients. Median sample frequency per patient was 3. During the first measurement only 38% of patients showed Cmin within the predefined target ranges: 52% of the patients showed a drug level below and 10% above target range. Dose interventions were proposed in 72 (66%) patients and implemented in 41 (38%) patients. In 35 out of 41 patients (85%) dose interventions led to an adequate Cmin. Eventually, 64% of the total cohort reached an adequate Cmin.

Characteristics Imatinib (n = 70) Sunitinib (n = 12) Pazopanib (n = 27) Total (n = 109)
Drug levels (n) 290 75 31 396
Drug levels per patient median (range) 3 (2-13) 2 (2-8) 3 (2-3) 3 (2-13)
Cmin Measurement First Last First Last First Last First Last
Adequate Cmin n (%) 29 (41) 42 (60) 7 (26) 20 (74) 5 (42) 8 (67) 41 (38) 70 (64)
Patients with interventions n (%) 20 (29) 17 (63) 4 (33) 41 (38)
Patients with adequate Cmin after intervention n (%) 19 (95) 13 (76) 3 (75) 35 (85)

Conclusions

This study shows that dose optimization is an effective tool to reach adequate Cmin for patients treated with IMN, SNN and PZN. Initially, only 38% of patients had an adequate Cmin. Of the patients undergoing dose intervention 85% reached an adequate Cmin. Plasma exposure awareness might add to the improvement of efficacy and toxicity of patients treated with IMN, SNN and PZN.

Clinical trial identification

Legal entity responsible for the study

Radboudumc

Funding

Radboud University Medical Center

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings